27
Participants
Start Date
November 5, 2023
Primary Completion Date
January 31, 2026
Study Completion Date
February 28, 2026
INZ-701
Recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.
Control Arm (Conventional Therapy)
Conventional therapy is defined as oral phosphate supplements and calcitriol or other active forms of vitamin D3 (or analogs). No other agents for treatment of ENPP1 Deficiency are allowed in the control arm.
Queensland Children's Hospital, South Brisbane
King Faisal Specialist Hospital and Research Centre, Riyadh
The Children's Hospital of Philadelphia, Philadelphia
Al Jalila Children's Specialty Hospital, Dubai
Umraniye Training and Research Hospital, Istanbul
Nationwide Children's Hospital, Columbus
Ann & Robert H. Lurie Children's Hospital, Chicago
Cook Children's Medical Center, Fort Worth
Children's Hospital of Colorado, Aurora
Hôpital Bicêtre, Service d'endocrinologie et diabète de l'enfant (Childhood Endocrinology and Diabetes Department), Le Kremlin-Bicêtre
Boston Children's Hospital, Boston
Centre Hospitalier Universitaire (CHU) Sainte-Justine, Montreal
Hospital San Joan de Deu, Barcelona
Cukurova Universitesi Tip Fakultesi, Sarıçam
Royal Manchester Children's Hospital, Manchester
Lead Sponsor
Inozyme Pharma
INDUSTRY